Aclaris Therapeutics Inc. (ACRS)
The price, the headline numbers and the latest news, in one place.
Aclaris Therapeutics Inc. (ACRS) Stock Price, Analysis & Data
| Bid | 4.41 |
| Market Cap | 884.67M |
| Revenue (ttm) | 8.22M |
| Net Income (ttm) | -75.74M |
| 0.78 | |
| -0.57 | |
| n/a | |
| -7.4 | |
| P/B (ttm) | 6.75 |
| P/S (ttm) | 107.64 |
| Earnings Date | Nov 5, 2026 |
| Ask | 7.2 |
| Volume | 1,220,839 |
| Avg. Volume (20D) | 1,893,263 |
| Open | 6.10 |
| Previous Close | 6.16 |
| Day's Range | 5.95 - 6.17 |
| 52-Week Range | 1.74 - 6.60 |
| Analyst | Strong Buy |
| Price Target | 10 (66.39%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ACRS
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to s...
Financial Performance
In 2025, Aclaris Therapeutics's revenue was 7.83M, a decrease of -58.19% compared to the previous year's 18.72M. Earnings were -64.92M, a decrease of -50.84%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for ACRS stock is "Strong Buy". The 12-month stock price forecast is 10, which is upside of 66.39% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $1.63M misses estimates by $0, with -8.33% YoY decline.
- EPS of -0.15 exceeds estimates by 0.01, with -15.38% YoY decline.
Analysts project revenue of ... Upgrade
